ABSTRACT

Objective: The objective of the study is to assess the prevalence of depression among patients with cardiovascular disease and its association with the use of β-blockers and statins.

Methods: This is a prospective observational study conducted at a corporate hospital, Hyderabad, Telangana, India, for a period of 6 months. 250 cardiac patients above 16 years are included in the study. The required data are collected from the patients through direct interview using standard questionnaires and also from patients’ respective case sheets. The acquired data are evaluated based on the standard questionnaires Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory-II (BDI-II) scales; used to diagnose the severity of depression in cardiac patients.

Results: Prevalence of minor to major depressive symptoms according to BDI-II was found to be 17.2%. Prevalence of minor to major depressive symptoms according to PHQ-9 was found to be 19.2%. Among male patients, 13% showed depressive symptoms, whereas among female patients 25% showed depressive symptoms. Among the patients coadministering beta-blockers and statins, 15% were depressed according to BDI-II, and 16% were depressed according to PHQ-9 at visit. After 1 month (first follow-up), the percentage increased by 6% (for BDI-II)-12% (for PHQ-9) and remains almost the same at the second follow-up. As per BDI-II and PHQ-9 scores, the percentage of patients with minor to major depression among the patients using only beta-blockers decreased significantly from the time of visit to the second follow-up. The percentage of patients with minor to major depression among the patients using only statins increased significantly from the time of visit to second follow-up.

Conclusion: Prevalence of minor to major depression according to BDI-II was found to be 17%, whereas according to PHQ-9, it was found to be 20% in patients with cardiovascular disease. Cardiovascular diseases have been more prevalent in men than in women, whereas depressive symptoms have been more prevalent in women than in men. Patients using only β-blockers showed a decrease in symptoms of depression. Whereas statins have shown to increase the chances of depression slightly which is often negligible, atorvastatin was associated with a higher level of depression when compared to rosuvastatin. Controversies still exist that statins decrease risk of depression.

Keywords: β-Blockers, Depression, Statins, Cardiovascular diseases, Psychological aspects, Screening.

INTRODUCTION

Depression and heart diseases go hand in hand and are among the most disabling diseases we face [1]. Cardiovascular disease (CVD) patients with depression have a worse outcome than those patients without it [2]. The drugs commonly used by CVD patients, i.e. lipophilic beta-blockers and statins are said to have a relationship with respect to increased risk of depressive symptoms. Especially, metoprolol (lipophilic beta blocker) and atorvastatin (statin) appear to increase the risk of depression according to a few recent studies [3]. Few studies were investigated that the effects of statins specifically on mood have reported mixed findings, with some suggesting an increased risk of depression, while others have found no association between statin use and mood disturbances or that statins, in fact, may protect against the risk of depression [3,4]. Beta-blockers or statins are chief support of CVD. With depression associated with some suggesting an increased risk of depression, while others have shown to increase the chances of depression slightly which is often negligible, atorvastatin was associated with a higher level of depression when compared to rosuvastatin. Controversies still exist that statins decrease risk of depression.

Possible link between statins and depression

It is suspected that hundreds of cases of statin-associated hostility, aggression, irritability, paranoia, homicidal ideation, depression, and suicide are somehow linked to dolichols and altered cell messaging. The main function of dolichol (dolichyl phosphate) is its participation in glycoprotein synthesis, and this lipid probably has no other major role in cellular processes [3]. The decrease in the levels of dolichols or its inhibition in the downstream of the mevalonate pathway may possibly cause depression [9-11].

Objectives

The objective of the study is to assess the prevalence of depression in cardiac patients. The secondary objective of the study is as follows:

- To assess the severity of CVD and depression among men and women.
- To assess the depression in patients using beta-blockers and statins concomitantly.
• To assess the depression in patients using only beta-blockers.
• To assess the depression in patients using only statins.

METHODS

Study protocol
It is a prospective study conducted for a period of 6 months and about 250 patients met the study criteria were included in the study. The required data are collected from the patients through direct interview using standard questionnaires and also from patients’ respective case sheets. The acquired data are evaluated based on the respective questionnaire scales and are used to measure the severity of depression in cardiac patients.[12-14]

Study site
The study was conducted at a corporate hospital in the city of Hyderabad, Telangana, India.

Study design
It is a prospective observational study, wherein standard questionnaire tools, i.e., Patient Health Questionnaire-9 (PHQ-9) and BDI-II are used to diagnose the severity of depression in cardiac patients.[15,16]

Study period
The study period was 6 months (5 months follow-up period).

Study population
A total of 250 patients are included in the study, of which 150 patients belonged to the in-patient department and 100 patients belonged to the out-patient department.

Study criteria
Inclusion criteria
• All the patients above the age of 16 years are included in the study.
• All male and female patients, including pregnant women with cardiac diseases, who are able to answer the given questionnaires are included.

Exclusion criteria
The following criteria were excluded from the study:
• Patients below the age of 16 years.
• Patients without any cardiac complications.

RESULTS AND DISCUSSION

Prevalence of depression in cardiac patients
• Prevalence of minor to major depressive symptoms according to BDI-II was found to be 17.2%.
• Prevalence of minor to major depressive symptoms according to PHQ-9 was found to be 19.2%.
• Among male patients, 13% showed depressive symptoms, whereas among female patients, 25% showed depressive symptoms.

Distribution based on BDI-II scores
A total of 250 cardiac patients were screened for depression using BDI-II and PHQ-9. According to BDI-II scores, of 250 patients, 68% were normal, 15% showed mild mood disturbances, 9% had borderline clinical depression, 6% were moderately depressed, and 2% suffered from severe depression. Prevalence of borderline to severe depression in cardiac patients according to the BDI-II scores was found to be 17% as shown in Fig. 1.

Distribution based PHQ-9 scores
According to PHQ-9 scores, of 250, 46 were normal, 34% showed minimal symptoms, 13% had mild depression, 6% were moderately

Fig. 1: Distribution based on levels of depression according to the Beck Depression Inventory-II scores

Fig. 2: Distribution based on levels of depression according to Patient Health Questionnaire-9 scores

Fig. 3: Distribution of patients using beta-blockers plus statins based on Beck Depression Inventory-II scores

Fig. 4: Distribution of patients using beta-blockers plus statins based on the Patient Health Questionnaire-9 scores
Prevalence of mild to major depression in cardiac patients according to PHQ-9 scores was found to be 20% as shown in Fig. 2.

**Distribution based on beta-blockers and statins use**

Of 250 patients, 159 used beta-blockers plus statins concomitantly. From the time of visit to the second follow-up, the number of patients suffering from depression increased. It is clear from the graph that the number of patients who were normal at the visit decreased from 111 at visit to 93 on second follow-up (after 2 months). Number of people with mood disturbances increased, this may be a sign that the condition may further lead to an increase in the severity of depressive symptoms. For patients with moderate depression, the number has increased from 5 patients at visit to 15 patients on the second follow-up as shown in Fig. 3.

According to PHQ-9 scores, number patients with minimal to moderate depression are highest during the first follow-up. Number of patients with major depression has doubled from the time of the visit to the second follow-up as shown in Fig. 4.

**Prevalence of minor to major depression among the patients using beta-blockers plus statins**

Among the patients coadministering beta-blockers and statins, 15% were depressed according to BDI-II, and 16% were depressed according to PHQ-9 at visit. After 1 month (first follow-up), the percentage increased by 8% (for BDI-II)-12% (for PHQ-9) and remains almost the same at the second follow-up (Fig. 5).

**Distribution of patients based on beta-blockers use**

A total of 26 patients used only beta-blockers. Among these patients, 15% were normal, patients with mood disturbances increased from 5 patients at visit to 10 patients during the second follow-up. There was a decrease in a number of patients with mild to moderate depression from the time of visit to second follow-up as shown in Fig. 6.

According to PHQ-9 scores, in patients using only beta-blockers, there was a decrease in the number of patients with minor to major depression from the time of visit to second follow-up as shown in Fig. 7.

**Comparison of BDI-II and PHQ-9 scores in the patients using beta-blockers**

As per BDI-II and PHQ-9 scores, the percentage of patients with minor to major depression among the patients using only beta-blockers decreased significantly from the time of visit to the second follow-up as shown in Fig. 8.

**Percentage of patients with minor to major depression based on the beta-blocker used**

Prevalence of depression in patients using metoprolol has increased from the time of visit to first follow-up and decreased again in the second follow-up, while in carvedilol users it was a quiet contrast scenario with decreased prevalence of depressive symptoms at first follow-up. Prevalence of minor to major depression among the patients using metoprolol has increased from the time of visit to first follow-up and decreased again in the second follow-up, while in carvedilol users it was a quiet contrast scenario with decreased prevalence of depressive symptoms at first follow-up.
follow-up and a steep rise in prevalence was observed at the second follow-up as shown in Fig. 9.

**Distribution based on statins use**

A total of 43 patients used only statins. According to the BDI-II scores, in patients using only statins, there was no significant difference between the number of patients with moderate to severe depression from the time of visit to second follow-up. However, there was a slight increase in number patients with borderline clinical depression or mild depression from visit to second follow-up as shown in Fig. 11.

There was an increase in moderate - major depression from the time of visit to the second follow-up, whereas number of patients with minimal symptoms and mild depression decreased from the time of visit to the second follow-up as shown in Fig. 11.

**Comparison of BDI-II and PHQ-9 score in the patients using only statins**

The percentage of patients with minor to major depression among the patients using only statins increased significantly from the time of visit to second follow-up as shown in Fig. 12.

**Distribution based on the type of statins**

From the time of the visit to the second follow-up, the percentage of patients with depression has increased from 16.6% to 22.7% according to BDI-II score in case of atorvastatin users and 12.1–15.60% according to PHQ-9 score in case of rosuvastatin users. It is clear that the prevalence of depression in atorvastatin users is higher than that of rosuvastatin users as shown in Fig. 13.

Screening for depression was done using the two standard questionnaires. Throughout the study period, on an average 17.2% of the whole study population were found to exhibit symptoms of depression based on BDI-II score. In accordance with the PHQ-9 scores, 19.2% of total study population exhibited minor to major depression. Almost about 3/4 of the population (i.e., 73%) hold to be males, and the rest 1/4 (i.e., 27%) were females. Therefore, it's a clear indication that males are more affected by cardiovascular diseases as compared to females. The reason for this might be several lifestyle factors that differ in men and women. Smoking has been the paramount risk factor for CVD and men are more prone to the habit of smoking than women, in a country like India. This might be one of the reasons why the study showed that a high percentage of men with coronary artery disease. Hence, it is assumed that exposure to endogenous estrogens during the fertile period of life delays the manifestation of atherosclerotic disease in women.

Depression is approximately twice as prevalent among women as it is among men. The results in the present study show that on an average 23 of 68 females (33%) and 42 of 182 males (23%) have observed to have minor-major depression (BDI-II score >16; PHQ-9 score >9). Thus, it conveys that females are 1.5 times more affected with depression than males. Many have attributed this disparity to the various stresses women face as a result of their gender and the demands women confront as they occupy multiple and often conflicting roles within the family, in the community, and at work.

Our study predicates that concomitant use of beta-blockers and statins may increase the chances of having depression. Although no evidence of such interaction has been mentioned in previous studies, the statement is completely contingent on our observations in the study population. Further, studies in this aspect may provide us with better evidence.

Patients using beta-blockers experienced a reduction in depression during the course of the study, but most of them had mild mood disturbances after a 3 month follow-up. In connection to the above observations, statins might not show a greater degree of variability in psychological aspects of a patient. Yet, slight increase in depressive symptoms seems to occur with statin use which may often be overlooked. A pile of studies were done by researchers in relation to this facet but failed to establish a clear association between statins and depression. Researchers have put forth number of hypotheses; one such hypothesis affirms that depression in patients using beta-blockers may be due to the cholesterol-lowering effect of statins in brain. Individuals who take statins to lower their cholesterol sometimes display symptoms of irritability, anxiety, and depression; these symptoms are reported by their family members, caregivers, and coworkers.

**CONCLUSION**

- Prevalence of minor to major depression according to BDI-II was found to be 17%.
- Prevalence of minor to major depression according to PHQ-9 was found to be 20%.
- Cardiovascular diseases have been more prevalent in men than in women whereas depressive symptoms have been more prevalent in women than in men.
- Use of beta-blockers and statins concomitantly may lead to a slight increase in depressive symptoms. Therefore, in patients who are on both the medications, there is a need for screening of depressive symptoms and monitor the patients’ status from time to time.
- The study reveals that the use of beta-blockers is not associated with an increase in depression. In fact, it has shown to decrease the symptoms of depression in cardiac patients who were on beta-blocker therapy.
Table 1: PHQ-9 score scale

<table>
<thead>
<tr>
<th>PHQ-9 score</th>
<th>Provisional diagnosis</th>
<th>Treatment recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5–9</td>
<td>Minimal symptoms</td>
<td>Support, educate to call if worse, return in 1 month</td>
</tr>
<tr>
<td>10–14</td>
<td>Minor depression, dysthymia, major depression, and mild anxiety</td>
<td>Support, watchful waiting, antidepressant or psychotherapy</td>
</tr>
<tr>
<td>15–19</td>
<td>Major depression, and moderately severe depression</td>
<td>Antidepressant or psychotherapy</td>
</tr>
<tr>
<td>&gt;20</td>
<td>Major depression, severe</td>
<td>Antidepressant or psychotherapy (especially if not improved on monotherapy)</td>
</tr>
</tbody>
</table>

PHQ-9: Patient Health Questionnaire-9

Table 2: Level of depression

<table>
<thead>
<tr>
<th>Total score</th>
<th>Level of depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–10</td>
<td>Normal</td>
</tr>
<tr>
<td>11–16</td>
<td>Mild mood disturbance</td>
</tr>
<tr>
<td>17–20</td>
<td>Borderline clinical depression</td>
</tr>
<tr>
<td>21–30</td>
<td>Moderate depression</td>
</tr>
<tr>
<td>31–40</td>
<td>Severe depression</td>
</tr>
<tr>
<td>&gt;40</td>
<td>Extreme depression</td>
</tr>
</tbody>
</table>

- Use of statins was observed to increase the chances of depression slightly which is often neglected as the symptoms may not be severe and may be often under-diagnosed.
- Atorvastatin was associated with a higher level of depression when compared to Rosuvastatin.
- Screening of the depression in cardiovascular patients should be made obligatory as its prevalence is significant.

ACKNOWLEDGMENT

The authors wish to thank the management of School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India, for providing necessary equipment for research, constant encouragement, facilities, and support. We personally thank Dr. Anand V Joshi, Intensivist, Sunshine Hospital, Gachibowli, Hyderabad, without whom the research work would not have been possible in the way it has been completed. We feel privileged for his constant guidance, motivation, and encouragement, for facilitating, sequencing our approach in the research work, and for all the requirements. We also thank all the hospital staff for all their cooperation extended in this research.

AUTHOR’S CONTRIBUTION

All authors contributed to the design and implementation of the research, to the analysis of the results and the writing of the final manuscript. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES